Viatris is a new kind of global healthcare company formed through the combination of Mylan and Upjohn, a legacy division of Pfizer.

Our mission is to empower people worldwide to live healthier at every stage of life by expanding access to medicines regardless of geography or circumstance; advancing responsible, sustainable operations and targeted innovation to improve patient health; and leveraging its collective expertise to connect more people to more products and services.

With a workforce of approximately 45,000 colleagues, Viatris is headquartered in the U.S. and has global centres in Pittsburgh, Shanghai and Hyderabad, India. Its global portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized iconic brands, generic, complex generic and branded medicines, a growing portfolio of biosimilars, and a variety of over-the-counter consumer products.

Viatris provides trusted, high-quality medicines that treat 9 out of 10 of the World Health Organization’s (WHO) leading causes of death. Viatris is a leading provider of antiretrovirals to treat HIV/AIDS and other infectious diseases. Approximately 23 million people have HIV worldwide. Over 40 percent of these people are treated with our products. 60 percent of children with HIV worldwide receive Viatris HIV treatment.

We have one of the strongest global commercial infrastructures in the industry, with a team of sales and marketing professionals providing unparalleled reach across North America, Europe, the Asia Pacific region and emerging markets. Our four business segments – Developed Markets, Growth Markets, Greater China, and Japan, Australia and New Zealand (JANZ) – serve patients through more than 60,000 customers, including retail and pharmacy establishments, wholesalers, governments, institutions, physicians and other customers. 

We have approximately 50 manufacturing facilities around the world and our strong technical resources are comprised of more than 2,500 scientists, more than 1,000 regulatory experts, and more than 600 medical and product safety professionals worldwide.

To learn more about our new company, please read our press release introducing Viatris, and visit You can also stay connected with us on Twitter (@ViatrisInc), LinkedIn and YouTube.

For any questions or additional information on Viatris and the company portfolio, please do not hesitate to reach out to your local representative.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971; Fax: + 353 1 6762517. Website: E-mail: Adverse events should also be reported to Viatris on +44(0)800 1218267 or

NON-2020-2952 November 2020                                                                  © 2020 – Viatris – All rights reserved